Attempt SuicideVGTSANCT02001649
Genetic Variants Associated With Adolescent Suicide Attempts
A study testing SNP Genotyping in people with Attempt Suicide, run by University Hospital, Rouen at 1 site in France.
Trial summary
Suicidal behaviors is known to aggregate in families. The purpose of this study is to evaluate association between common polymorphisms in genes important for neurobiological pathways linked to suicidal behaviors and suicide attempt among adolescents patient. Read more about this study
- Who is it for?
- Ages 13 to 17 yearsHealthy volunteers can take part
- Conditions the study is for
- Attempt Suicide
- What is being tested?
- SNP Genotyping
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 250 participants
- Where
- 1 siteFrance
- Study dates
- Dec 2013to Jul 2016
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 13 to 17 years
- All sexes
- Healthy volunteers accepted
- Child
Who may be able to join
- Case :
- Age at admission between 13 and 17 years old
- Hospitalized for attempted suicide
- Absence of prominent mental retardation or organic brain damage
- Fluent in French
- Able to comprehend the study procedures and to undergo entry assessments safely
Show all 16Show fewer
- Provided written informed consent for study participation, and additional consent from the patient's parents or guardians
- Northern and Western European ancestry (HapMap-CEU)
- Medical insurance coverage
- Control :
- Healthy adult volunteers
- No present or past psychiatric illness
- No personal history of suicidal behavior and without a family history of suicide
- Provided written informed consent for study participation
- Northern or Western European ancestry (HapMap-CEU)
- Medical insurance coverage
Who cannot join
- Case:
- Inability to get an informed and valid consent
- Home address outside the selected hospitals' geographic areas
- Intellectual disability or organic brain damage
- Origine ethnique non CEU
- Absence of medical insurance coverage
Show all 18Show fewer
- Pregnant or lactating women
- Without Northern or Western European ancestry (HapMap-CEU)
- Control :
- Inability to get an informed and valid consent
- Intellectual disability or organic brain damage
- History of suicidal behavior
- Psychiatric disorder, past or present
- Family history of suicide
- Borderline personality disorder
- Absence of medical insurance coverage
- Pregnant or lactating women
- Without Northern or Western European ancestry (HapMap-CEU)
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Genetic Variants Associated With Adolescent Suicide Attempts: a Candidate-gene Association Study.
Suicidal behaviors is known to aggregate in families. The purpose of this study is to evaluate association between common polymorphisms in genes important for neurobiological pathways linked to suicidal behaviors and suicide attempt among adolescents patient.
Read the detailed description
In France, suicide is the second leading cause of death among the 14-22 years population. Suicide behavior (SB) spans a spectrum ranging from suicidal ideation to suicide attempts and completed suicide. Several factors likely determine the predisposition to SB, including biological factors and psychosocial stressors. For biological factors, convergent evidence from adoption, family, and twin studies of suicide strongly suggests genetic contributions to liability for SB. Although genetic factors play a role in SB, identifying specific genes involved has proved challenging. Molecular-genetic technologies have made great advances in the past decade, including genome- wide searches for disease-causing genes with the linkage disequilibrium (LD) approach. Despite being a major public health problem in the youth population, genetic associations studies regarding suicidal behavior in adolescence are still rare. Genes that code for proteins involved in regulating serotonergic neurotransmission have thus been major candidate genes for association studies of SB. Among them, genes for serotonin metabolism (tryptophan hydroxylase, TPH), serotonin transport (5-HTT), and the serotonergic 2A (5-HT2A) receptor have received the most research attention.
The identification of relevant genetic variants or SNPs in others genes which are involved in the neurobiological pathways (which the alteration may contribute to a suicidal behavior) can help not only to advance knowledge of the genetic bases of suicide but also to identify new therapeutic targets.
On the basis of review of the literature, investigators will identify candidate genes that have been reported to be associated with suicidal events.
The investigators will target genes related to central serotonergic and noradrenergic neurotransmission, and monoamine metabolism (MAOA). The investigators will also study genes involved in glutamatergic neurotransmission (GRIK2, GRIA3) and in the HPA axis (FKBP5) and genes that code for neurotrophic proteins (BDNF).
DNA will be obtained from saliva. All genotyping will be carried out using standard polymerase chain reaction-based techniques that are routinely used in the Human Genetics Laboratory. DNA segments containing the target variable site will be amplified using unique sequence flanking primers.
Tests of association between genetic variant and suicide attempt will be conducted using Chi squared and Armitage Trend Tests. Logistical regression analyses will be performed to evaluate the contribution of individual genetic variant to the prediction of suicide attempt, and to examine SNPs for potential gene-gene and gene-environment interactions.
- Conditions
- Attempt Suicide
- Being tested
- SNP Genotyping
- Keywords
- suicide, adolescent, genetic, SNP
- Medical subject headings
- Suicide, Attempted, Suicide
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
SNP GenotypingGenetic
Individuals were genotyped at a total 96 SNP from 15 candidate gene
SNP genotypingGenetic
| Study group | Role | What they receive |
|---|---|---|
| Inpatient group SNP Genotyping | Other | Patients will be recruited from pediatric departments in which 13 -17 y old adolescents are hospitalized for a suicide attempt. Data will be collected through self-administered questionnaires and face to face interview. DNA will be extracted from saliva sample.
Individuals will be genotyped at a total of 96 SNPs Receives: Genetic: SNP Genotyping |
| Control group SNP Genotyping | Other | Control subjects are young adults without suicide attempt and without mental disorders Receives: Genetic: SNP genotyping |
What is being measured
The primary outcome is the main question the study is designed to answer.
Odds ratio (OR) and 95% confidence interval (CI) will be estimated using a logistic regression model to assessing the contribution of each polymorphism as a risk factor in predicting suicidal behavior
Measure is a composite outcome measure consisting of multiple measures
Post hoc Bonferroni correction will be employed to correct for multiple testing.
Chi- square test will performed to analyze genetic associations
Measured: Between day 1 and day 5 during hospitalization
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted5 Dec 2013 (estimated)
- Study startDec 2013
- Primary completionJul 2016
- Study completionJul 2016
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Attempt SuicideStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Screening
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 250 participants (actual)
Sponsor and investigators
- Lead sponsor
- University Hospital, Rouen
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- BOJAN MIRKOVIC, MD, Principal investigator, CHU Rouen, Fédération de pédopsychiatrie du Pr Gérardin
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02001649
- Sponsor's protocol ID
- 2013/092/HP
- Acronym
- VGTSA
- Status last verified
- Apr 2026
- First submitted
- 14 Nov 2013
- Last updated
- 16 Apr 2026
- Results posted
- No
- Data monitoring committee
- No
Publications
Mirkovic B, Cohen D, Laurent C, Lasfar M, Marguet C, Gerardin P. A case-control association study of 12 candidate genes and attempted suicide in French adolescents. Int J Adolesc Med Health. 2017 Sep 13;32(1):/j/ijamh.2020.32.issue-1/ijamh-2017-0089/ijamh-2017-0089.xml. doi: 10.1515/ijamh-2017-0089.
PubMed 28902619
Study at a glance
From the registry record, last updated by the sponsor on 16 Apr 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Genetic Variants Associated With Adolescent Suicide Attempts: a Candidate-gene Association Study.
- ClinicalTrials.gov ID
- NCT02001649
- Acronym / sponsor ID
- VGTSA / 2013/092/HP
- Conditions
- Attempt Suicide
- Keywords
- suicide, adolescent, genetic, SNP
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 250 participants (actual)
- Lead sponsor
- University Hospital, RouenUniversity, hospital or other
- Collaborators
- Institut National de la Santé Et de la Recherche Médicale, France
- Study start
- Dec 2013
- Primary completion
- Jul 2016 (actual)
- Study completion
- Jul 2016 (actual)
- First posted
- 5 Dec 2013 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Suicidal behaviors is known to aggregate in families. The purpose of this study is to evaluate association between common polymorphisms in genes important for neurobiological pathways linked to suicidal behaviors and suicide attempt among adolescents patient.
Detailed description
In France, suicide is the second leading cause of death among the 14-22 years population. Suicide behavior (SB) spans a spectrum ranging from suicidal ideation to suicide attempts and completed suicide. Several factors likely determine the predisposition to SB, including biological factors and psychosocial stressors. For biological factors, convergent evidence from adoption, family, and twin studies of suicide strongly suggests genetic contributions to liability for SB. Although genetic factors play a role in SB, identifying specific genes involved has proved challenging. Molecular-genetic technologies have made great advances in the past decade, including genome- wide searches for disease-causing genes with the linkage disequilibrium (LD) approach. Despite being a major public health problem in the youth population, genetic associations studies regarding suicidal behavior in adolescence are still rare. Genes that code for proteins involved in regulating serotonergic neurotransmission have thus been major candidate genes for association studies of SB. Among them, genes for serotonin metabolism (tryptophan hydroxylase, TPH), serotonin transport (5-HTT), and the serotonergic 2A (5-HT2A) receptor have received the most research attention.
The identification of relevant genetic variants or SNPs in others genes which are involved in the neurobiological pathways (which the alteration may contribute to a suicidal behavior) can help not only to advance knowledge of the genetic bases of suicide but also to identify new therapeutic targets.
On the basis of review of the literature, investigators will identify candidate genes that have been reported to be associated with suicidal events.
The investigators will target genes related to central serotonergic and noradrenergic neurotransmission, and monoamine metabolism (MAOA). The investigators will also study genes involved in glutamatergic neurotransmission (GRIK2, GRIA3) and in the HPA axis (FKBP5) and genes that code for neurotrophic proteins (BDNF).
DNA will be obtained from saliva. All genotyping will be carried out using standard polymerase chain reaction-based techniques that are routinely used in the Human Genetics Laboratory. DNA segments containing the target variable site will be amplified using unique sequence flanking primers.
Tests of association between genetic variant and suicide attempt will be conducted using Chi squared and Armitage Trend Tests. Logistical regression analyses will be performed to evaluate the contribution of individual genetic variant to the prediction of suicide attempt, and to examine SNPs for potential gene-gene and gene-environment interactions.
Study design
- Primary purpose
- Screening
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Inpatient group SNP Genotyping | Other | Genetic: SNP GenotypingPatients will be recruited from pediatric departments in which 13 -17 y old adolescents are hospitalized for a suicide attempt. Data will be collected through self-administered questionnaires and face to face interview. DNA will be extracted from saliva sample. Individuals will be genotyped at a total of 96 SNPs |
| Control group SNP Genotyping | Other | Genetic: SNP genotypingControl subjects are young adults without suicide attempt and without mental disorders |
Who may qualify
- Ages
- 13 to 17 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Child
Key inclusion criteria (16 listed)
- Age at admission between 13 and 17 years old
- Hospitalized for attempted suicide
- Absence of prominent mental retardation or organic brain damage
- Fluent in French
- Able to comprehend the study procedures and to undergo entry assessments safely
Key exclusion criteria (18 listed)
- Inability to get an informed and valid consent
- Home address outside the selected hospitals' geographic areas
- Intellectual disability or organic brain damage
- Origine ethnique non CEU
- Absence of medical insurance coverage
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| SNP GenotypingIndividuals were genotyped at a total 96 SNP from 15 candidate gene | Genetic | Inpatient group SNP Genotyping |
| SNP genotyping | Genetic | Control group SNP Genotyping |
Primary outcome
Odds ratio (OR) and 95% confidence interval (CI) will be estimated using a logistic regression model to assessing the contribution of each polymorphism as a risk factor in predicting suicidal behavior
Time frame: Between day 1 and day 5 during hospitalization
Measure is a composite outcome measure consisting of multiple measures Post hoc Bonferroni correction will be employed to correct for multiple testing. Chi- square test will performed to analyze genetic associations
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 16 Apr 2026.
- Results publication: PubMed 28902619Mirkovic B, Cohen D, Laurent C, Lasfar M, Marguet C, Gerardin P. A case-control association study of 12 candidate genes and attempted suicide in French adolescents. Int J Adolesc Med Health. 2017 Sep 13;32(1):/j/ijamh.2020.32.issue-1/ijamh-2017-0089/ijamh-2017-0089.xml. doi: 10.1515/ijamh-2017-0089.
Related trials for Attempt Suicide
Recruiting
Suicide Preventive Psychosocial Treatment for Youths
Suicide Attempt, Suicidal and Self-injurious Behavior
Recruiting
Evaluation of a Multi-Layered Digital Phenotyping, Digital Safety Plan, and Pharmacogenomic Intervention for Suicide Prevention in Adults With Depression
Depressive Disorder, Major Depressive Disorder, Suicidal Ideation
Not yet recruiting
THRIVE: A Recovery-Focused Suicide Prevention Intervention in Crisis Stabilization Centers
Suicide
Active, not recruiting
DBT Skills Groups for Veterans at High Risk for Suicide Attempt
Suicide, Attempted
Active, not recruiting
Cognitive Reappraisal Intervention for Suicide Prevention (CRISP 70+) for Suicidal Older Adults in a Swedish Geropsychiatric Setting
Suicidal Ideation, Suicide
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
BOJAN MIRKOVIC, MD principal investigator
CHU Rouen, Fédération de pédopsychiatrie du Pr Gérardin
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing SNP Genotyping in people with Attempt Suicide, run by University Hospital, Rouen at 1 site in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 16 inclusion and 18 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 16 Apr 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Odds ratio (OR) and 95% confidence interval (CI) will be estimated using a logistic regression model to assessing the contribution of each polymorphism as a risk factor in predicting suicidal behavior (time frame: Between day 1 and day 5 during hospitalization). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT02001649, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 16 Apr 2026.